Trial Profile
A Feasibility and Safety Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells in Patients With Metastatic, Locally Advanced, Unresectable, or Recurrent Pancreatic Adenocarcinoma.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Poly ICLC (Primary) ; Dendritic cell vaccines
- Indications Pancreatic cancer
- Focus Adverse reactions
- 08 Dec 2016 Status changed from active, no longer recruiting to completed.
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 15 Oct 2015 Planned primary completion date changed from 1 Nov 2015 to 1 Nov 2013 as reported by ClinicalTrials.gov.